Quality of life following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a Canadian experience.

ABSTRACT:

Background

Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is an effective treatment for select peritoneal surface malignancies, offering a survival benefit. However, the procedure can substantially impact patients' quality of life (QoL) owing to its physiologic and functional effects. We sought to evaluate QoL trajectories over 12 months following CRS/HIPEC and to identify factors influencing outcomes.

Methods

A prospective cohort study was performed including patients undergoing CRS/HIPEC between January 2018 and July 2022. Quality of life was assessed preoperatively and at 3, 6, and 12 months postoperatively using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-CR29 questionnaires. Qualitat

SUBMITTER: Taqi K 

PROVIDER: S-EPMC12705204 | biostudies-literature | 2025 Nov-Dec

REPOSITORIES: biostudies-literature